Gradalis®, Inc. - formerly dba Murex Pharmaceuticals, Inc. - is a fully integrated biotechnology company focused on development, manufacturing, and commercialization of drugs, vaccines, tools, and diagnostics primarily in the area of cancer. Gradalis is organized around molecular based personalized therapeutics that are tumor specific, more effective and less toxic than current treatment modalities. The company has two primary platforms: one focused on personalized autologous vaccines and the other focused on bifunctional short hairpin RNA delivered via a proprietary lipoplex. Gradalis maintains a state of the art GMP manufacturing facility along with high-skilled technical leadership and staff. The company is developing treatments for advanced ovarian cancer (with a Phase III trial); advanced breast cancer (Phase II and III trials); and Ewings Sarcoma, advanced non-small cell lung cancer, gynecological cancer, and advanced melanoma (Phase 1 trials), according to a report in D CEO Healthcare.
